סיטאר פלוס 50/500 - Sitar plus 50/500
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | A10BD Combinations of oral blood glucose lowering drugs |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | Sitar plus is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus. Important limitations of use: Sitar plus should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. Sitar plus has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitar plus. |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ס×××ר פ××ס 50/500 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | LABORATORIOS LICONSA S.A., SPAIN |
| ×©× ××¢× ×ר×ש×× | UNIPHARM TRADING LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 6/2021. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 27/06/2024 |
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
- ×××¨× ×שפ××¢ ×¢× ××¢×××ת ××פ×ר××× ×××פ×× ×סר×× ×ער××× ×ת
- ×××©×¤×¢× ××××××× ×©× ××פ×ר××× ×¢× ××ס××××רתר×××ס
- ×× ×¦×××ת ×××ר×פ××ת- EMA ××¢× ××§× ××ש×ר ×תר××¤× Empagliflozin
- ×ת××¢×ת ×©× ××פ×× ×¢× ××פ×ר××× ××××× ×¡××רת ×¢× ××× ×××
- ××¢×××ת ××פ×× ×©×××¢× ×¢× ××§×¡× ×××× ××ת××ר×× ×¢× ×¡××רת ס×× 2
- ××פ×ר××× ×שר×××ת ××××פ××× ×¢× ×¡×¨×× ×¨××× ×××ª× × ×ª××
השינוי האחרון נעשה בֹ־27 ביוני 2024 ב־03:39